anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention comprises compounds of the formula <FORM:1086530/C2/1> in which R and R1 each represents a hydrogen atom or a C1- 4 alkyl or allyl group, or together form a -(CH2)ngroup where n is 4, 5 or 6, and X and Y each represents a hydrogen, chlorine, bromine or fluorine atom or a methyl, ethyl, cyano, trifluoromethyl, hydroxy, nitro, amino C1- 4 alkylamino, di(C1- 4 alkyl)amino, carboxy or methoxy- or ethoxy-carbonyl group; and their acid addition salts with acids having non-toxic anions.  The compounds are prepared by (a) hydrolysing or reducing corresponding 1-acylamino-4-phenyl-bicyclo[2,2,2]-octanes to form the corresponding 1-amino or 1-alkylamino compounds, or (b) ammonolysing or aminolysing methane sulphonic esters of 4-hydroxy -4-phenyl-bicyclo[2,2,2]octanes, or (c) reducing 4 - phenyl - bicyclo[2,2,2]oct - 2 - ene-1 -carboxylic acids or their esters to yield 4-phenyl - bicyclo[2,2,2]octane - 1 - carboxylic acids or esters, if necessary saponifying the esters to the free acids, and converting the acids by the Hofmann, Curtius or Schmidt reaction to 4-phenyl - bicyclo[2,2,2]octane - 1 - amines, or (d) alkylation of 4-phenyl-bicyclo[2,2,2]octane-1 -amines or -alkylamines, e.g. by reaction of alkyl halides or dialkyl sulphates in the presence of a base, or by acylation followed by reduction with lithium aluminium hydride of the resulting N -acyl-amine or N -acyl-N -alkylamine.  In a modification of process (d), compounds of Formula I in which R and R1 together form the divalent group -(CH2)nare made by reacting the primary amine with a dicarboxylic acid anhydride to form a corresponding N carboxyacyl-amine which is reduced and cyclized with lithium aluminium hydride.  Starting materials.-1-Acetamido-4-phenyl-bicyclo[2,2,2,]octane is prepared by reacting 4-hydroxy - 1 - phenyl - bicyclo[2,2,2]octan - 2-one with hydrazine to form the corresponding hydrazone, heating this with hydrazine, diethylene glycol and potassium hydroxide to form 4 - phenyl - bicyclo[2,2,2]octan - 1 - ol and reacting this with acetonitrile.  1-Acylamino-4-(substituted phenyl)-bicyclo[2,2,2]octanes are prepared by nitrating a 1-acylamino-4-phenyl-bicyclo[2,2,2]octane, reducing the nitro compound to the corresponding amino compound, diazotizing the amino compound and replacing the diazo group in the resulting compound by a hydroxy group by heating it in an aqueous solution or by a halogen atom or cyano group by reacting it with a cuprous halide or cuprous cyanide.  A resulting phenol may be alkylated to give the corresponding alkoxy compound, or a resulting nitrile may be hydrolysed to the corresponding carboxylic acid which may be converted to an ester or reacted with sulphur tetrafluoride to replace the carboxy group by a trifluoromethyl group.  If, instead of diazotization, the amino group is acylated and reduced with lithium aluminium hydride the corresponding mono- and di-alkylamino compounds are prepared.  Pharmaceutical compositions having anti-depressant activity, for oral or parenteral administration, comprise a compound of the invention together with a pharmaceutical carrier.
PROBLEM TO BE SOLVED: To watch the consultation information of a desired cell in detail by replacing a selected character string in the character string of an editing object with an emphasized character string stored corresponding to a convolved character string based on the selected character string. SOLUTION: In display object exchange processing, a text before convolution is deleted from an original text (A21). Next, a new object NewObj is generated and located (A23) and the emphasized character string as contents in a buffer StrAft is set to that object NewObj (A25). Besides, the ID thereof is allocated (A25). Thus, the selected character string is replaced with the emphasized character string stored corresponding to the convolved character string based on the selected character string. Thus, the consultation information of the desired cell can be watched in detail.
The present study aimed to investigate the role of PI3K‑mediated ferroptosis signaling induced by mild therapeutic hypothermia (MTH), which was defined as a temperature of 34˚C, in protecting against myocardial ischemia-reperfusion (I/R) injury (MIRI). To meet this aim, H9C2 cells underwent hypoxia‑reperfusion (H/R) and/or MTH. The MTT assay was used to assess cell viability, cytotoxicity was measured using a lactate dehydrogenase cytotoxicity assay, and Annexin V‑FITC/PI flow cytometric analysis was used to analyze early and late cell apoptosis. In addition, 84 healthy adult male Sprague‑Dawley rats were randomly divided into seven groups (n=12), and underwent I/R and various treatments. Hemodynamics were monitored, and the levels of myocardial injury marker enzymes and oxidative stress markers in myocardial tissue were measured using ELISA. The expression levels of PI3K, AKT, transient receptor potential cation channel subfamily M member 7 (TRPM7), glutathione peroxidase 4 (GPX4) and acyl‑CoA synthetase long chain family member 4 (ACSL4) in animals and cells were measured using western blot analysis. These experiments revealed that MTH could effectively reduce myocardial infarct size, improve hemodynamic performance following MIRI and suppress myocardial apoptosis, thereby contributing to the recovery from H/R injury. Mechanistically, MTH was revealed to be able to activate the PI3K/AKT signaling pathway in cells, upregulating GPX4, and downregulating the expression levels of TRPM7 and ACSL4. Treatment with 2‑aminoethoxydiphenyl borate (an inhibitor of TRPM7) could further strengthen the myocardial protective effects of MTH, whereas treatment with erastin (promoter of ferroptosis) and wortmannin (inhibitor of PI3K) led to the effective elimination of the myocardial protective effects of MTH. Compared with in the I/R group, the PI3K/AKT activation level and the expression levels of GPX4 were both significantly increased, whereas the expression levels of TRPM7 and ACSL4 were significantly decreased in the I/R + MTH group. Taken together, the results of the present study indicated that MTH may activate the PI3K/AKT signaling pathway to inhibit TRPM7 and suppress ferroptosis induced by MIRI.
BACKGROUND: Neutrophil-lymphocyte ratio (NLR) is a valuable indicator for evaluating inflammatory response and red blood cell distribution width (RBDW), a routinely available biomarker of likely erythropoietic dysfunction, which may be associated with adverse outcomes after cardiac surgery. This study aimed to investigate the association between these two readily available haematological parameters, with the poor outcomes in paediatric patients undergoing cardiac surgery.
METHODS: A comprehensive review of medical records for paediatric patients who underwent cardiac surgery at our tertiary care centre between April 2022 and June 2023 was carried out. RBDW and NLR values were collected from complete blood count reports obtained on admission to the ICU. Demographic data, surgical details, and postoperative complications were also recorded. A receiver operating characteristic (ROC) curve and multivariable logistic regression were applied to identify the prognosis performance of preoperative NLR and RBDW for poor outcomes.
RESULTS: The study included 219 patients meeting the inclusion criteria of which a total of 90 (41%) children experienced at least one of the poor outcomes. Preoperative NLR (AUC=0.88, 95%CI 0.36-0.70, cut off- 4.2) and RBDW (AUC=0.88, 95%CI 0.39-0.73, cut off- 18.5%) showed prognostic significance in the perioperative period.
CONCLUSION: This retrospective observational study highlights a significant association between elevated Red Blood Cell Distribution Width (RBDW) and Neutrophil Lymphocyte Ratio (NLR) values and poor outcomes in paediatric patients undergoing cardiac surgery. These readily available haematological parameters could serve as potential prognostic indicators for identifying patients at risk of poor outcomes.
Silica nanorings, methods of making silica nanorings, and uses of silica nanorings. The silica nanorings may be surface selective functionalization, with one or more polyethylene glycol (PEG) group(s), one or more display group(s), one or more functional group(s), or a combination thereof. The silica nanorings may have a size of 5 to 20 nm. The silica nanorings may be made using micelles. The absence or presence of the micelles during PEGylation and/or functionalization allows for the surface selective functionalization. The silica nanorings may be used in various diagnostic and/or treatment methods.
Lower-income and minority groups face significant health disparities with respect to obesity, cancer, heart disease and other chronic conditions. Poor diets, low in fruits and vegetables (F\&V) and high in saturated fat, sodium and sugar, contribute to many of the health problems faced by vulnerable groups. While poverty, low-educational attainment and personal food preference are all associated with reduced F\&V consumption, these individual-level factors must be viewed in an environmental context. Research has repeatedly demonstrated the important role that environment plays on health decisions and behaviors. Compared with higher-income neighborhoods, lower-income and minority neighborhoods are less likely to have a supermarket that sells a variety of F\&V and other healthy foods. This is perpetuated by an underlying misconception that there is limited demand or potential profit for new healthy food ventures in these communities. In the few cases where new food outlets have opened in underserved areas, they have been met with substantial customer support. The NC Green Cart program, which our team has already been funded to lead, uses a weekly mobile market model to deliver low-cost boxes of fresh F\&V to easily accessible community locations (such as churches and day care centers) and provide nutrition and cooking education. This program builds upon burgeoning support for a local sustainable food system in NC and leverages a public-private partnership to increase access to fresh F\&V in underserved communities. While current program funding allows for minimal evaluation, the present study hopes to demonstrate that selling affordable, accessible F\&V in lower-income communities is not only financially viable, but can impact behavioral risk factors of individuals in target communities. Working together with the Green Cart program team, this research will 1.) measure the impact of a mobile market at 6, 12 and 18 months on the primary outcome of F\&V consumption as well as BMI, perceived access to F\&V, and self-efficacy to purchase, prepare, serve and eat fresh F\&V using a randomized controlled design; and 2.) assess community support, feasibility, and financial sustainability of the public-private Green Cart partnership. Results of this research will inform our understanding of how the food environment impacts dietary choices and provide evidence for researchers, businesses, non-profits and policy makers on the potential impact and viability of using similar models to reduce food access disparities and improve diet.
A training method for imaging includes obtaining a dataset volume for an organ of a patient in an ultrasound imaging mode, and providing a template associated with the dataset volume to an optical ultrasound system location. The method also includes providing a virtual transducer with a label thereon to the optical ultrasound system location. A webcam is attached to the template. The webcam is positioned to view the label on the virtual transducer. The method includes determining the planar position of the virtual transducer from optical information obtained from the webcam image of the label. Once the planar position is determined, the planar position of the virtual transducer is related to the corresponding plane in the dataset. The plane related to the dataset is then displayed at the displaying the plane from the dataset at the optical ultrasound system location.
PURPOSE: A Houttuynia cordata THUNB. extract or a mixture of the Houttuynia cordata THUNB extract and an Ampelopsis radix extract is provided to protect cells, to improve recognition function, and to prevent and treat dementia, Parkinson's disease, or epilepsy. CONSTITUTION: A pharmaceutical composition for preventing and treating dementia, Parkinson's disease, or epilepsy contains a Houttuynia cordata THUNB. extract as an active ingredient. The extract is prepared using water, C_1-C_2 alcohol, or a mixture thereof. Dementia is selected from the group consisting of Alzheimer's disease, vascular dementia, and MCI(Mild Cognitive Impairment). A health food composition for preventing and treating dementia, Parkinson's disease, or epilepsy contains a Houttuynia cordata THUNB. extract as an active ingredient.
The present invention relates to a composition for lowering the blood sugar level comprising a Cirsium setidens extract as an active ingredient and a method for producing the same, Specifically, The Cirsium setidens extract is obtained by using Cirsium setidens with water, ethanol or a solvent mixed with water and ethanol so the composition is nontoxic and harmless, reduces a blood sugar level. The Cirsium setidens extract contains water, ethanol or a mixed plant extract extracted by the solvent mixed with water and ethanol. The mixed plant extract consists of Cymbidium kanran, Bletilla striata and Sparganii Rhizoma. As the Cirsium setidens extract is mixed with the mixed plant extract, the blood sugar level in bodies can be effectively reduced by improving alpha-glucosidase inhibitory activities and alpha-amylase inhibitory activities. Lactobacillus is inoculated into the mixed plant extract, and the fermented and aged plant extract is contained in the Cirsium setidens extract, so alpha-glucosidase inhibitory activities and alpha-amylase inhibitory activities are increased. Accordingly, the blood sugar level in bodies can be effectively reduced.
Delivered subcutaneously (SC) every 3 weeks (Q3W) for 24 weeks in the placebo-controlled treatment period. After completion of the placebo-controlled treatment period, placebo participants will enter into 1 of the 2 sotatercept dose groups in an extension period.
The use of attenuated Salmonella strains that are unable to cause clinical disease but trigger a self-limiting infection leading to stimulation of protective immunity presents an attractive alternative to killed and subunit vaccines. Live, attenuated Salmonella strains have been shown to be excellent carriers, or vectors, for prokaryotic or eukaryotic antigens, being able to stimulate strong systemic and local immune responses against the expressed antigens. Three Salmonella Typhi strains have been engineered to express a gene encoding the alpha-helical domain of the Streptococcus pneumoniae surface protein, PspA, and will serve as live biological vaccine vectors in the proposed clinical trial to evaluate maximum safe and tolerable single dose levels after their oral administration to subjects. In this Phase I study, healthy young adults 18-40 years of age will participate in a dose escalating, dose sequential study divided into four Arms to receive doses of 10\^7, 10\^8, 10\^9 and 10\^10 CFU. Each Arm (1-4) will consist of 3 groups of 5 subjects per group to receive a single oral dose of one of three recombinant attenuated S. Typhi vaccine vectors producing the pneumococcal antigen PspA. Each group per Arm will receive the same dose of one of the three vaccines for a total of 60 subjects (15 subjects per dose-escalating Arm, 3 groups per Arm, 5 subjects per group). Subject participation lasts 6 months after receiving the oral vaccine dosage with approximately the first 12-15 days (study Days 0-14) in confinement. Release criteria include 2 negative blood cultures in a row through study Day 7 (inpatient monitoring for 8 days) and 2 negative stool cultures in a row through study Day 5. The objectives of the study are 1) to evaluate maximum safe tolerable single dose levels of the three recombinant attenuated S. Typhi vaccine vectors using dose-escalation, dose-sequential studies in healthy adult subjects, and 2) to evaluate immunogenicity of the three recombinant attenuated S. Typhi vaccine vectors with regard to their abilities to induce mucosal and systemic antibody responses to the S. pneumoniae PspA and S. Typhi antigens. The vaccines are not anticipated to prevent disease. Although the immune responses generated by the vaccine vectors may confer some degree of protection against future infection with S. pneumoniae and S. Typhi, such protection is incidental. It is not the goal of this study to develop or test either a pneumonia or typhoid vaccine, but to select the S. Typhi vector that provides optimal delivery of the PspA antigen in a safe and immunogenic manner.
Age-related chronic inflammatory lung diseases impose a threat on public health, including idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). However, their etiology and potential targets have not been clarified. We performed genome-wide meta-analysis for IPF with the largest sample size (2883 cases and 741,929 controls) and leveraged the summary statistics of COPD (17,547 cases and 617,598 controls). Transcriptome-wide and proteome-wide Mendelian randomization (MR) designs, together with genetic colocalization, were implemented to find robust targets. The mediation effect was assessed using leukocyte telomere length (LTL). The single-cell transcriptome analysis was performed to link targets with cell types. Individual-level data from UK Biobank (UKB) were used to validate our findings. Sixteen genetically predicted plasma proteins were causally associated with the risk of IPF and 6 proteins were causally associated with COPD. Therein, genetically-elevated plasma level of SCARF2 protein should reduce the risk of both IPF (odds ratio, OR = 0.9974 [0.9970, 0.9978]) and COPD (OR = 0.7431 [0.6253, 0.8831]) and such effects were not mediated by LTL. Genetic colocalization further corroborated these MR results of SCARF2. The transcriptome-wide MR confirmed that higher expression level of SCARF2 was associated with a reduced risk of both. However, the single-cell RNA analysis indicated that SCARF2 expression level was only relatively lower in epithelial cells of COPD lung tissue compared to normal lung tissue. UKB data implicated an inverse association of serum SCARF2 protein with COPD (hazard ratio, HR = 1.215 [1.106, 1.335]). The SCARF2 gene should be a novel target for COP.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes new monoester compounds of the general formula (I): Nu-O-Fa where values Nu and Fa are given in p. 1 of the invention claim. Compounds can be used for treatment of humans and animals suffering with the viral infection. Invention describes also a pharmaceutical composition based on compounds of the formula (I). EFFECT: new compounds indicated above, an antiviral activity. 8 cl, 17 dwg, 1 tbl, 10 ex
Systems and methods for automated path planning of a surgical procedure, such that the optimal approach is selected from among a series of potential choices. The system is configured to plan and carry out, using a robotic surgical system, access to a surgical site starting from selection of the skin entry point. The methods select the best surgical approach and plan the physical path for robotically performing a selected surgical procedure. The path finding method uses preoperative MRI or CT images and computer vision or other image processing method to identify specific organs and tissues. The method then assigns values to a variety of parameters that define the tissue compressibility, penetrability, flexibility, and other characteristics. The system then plans an optimal path to reach the surgical target area with minimum danger of tissue damage and maximum patient safety, and encodes this information for execution by a robotic system.
In experimental group, Ganoderma Spores Powder Capsules for 12 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
The development of a medication to treat cocaine addiction specifically by lessening withdrawal symptoms has been a primary focus of research. Common cocaine withdrawal symptoms include depression, lack of energy, and poor concentration. Modafinil, a central nervous system stimulant, is a medication that can speed up physical and mental processes in the brain. It is currently used to treat narcolepsy, a condition that causes excessive sleepiness. Modafinil enhances mood, increases energy, and improves concentration in people with narcolepsy. Modafinil may also cause the same effects in individuals addicted to cocaine, thereby countering the symptoms of cocaine withdrawal. The purpose of this study is to compare the effectiveness of modafinil plus CBT versus placebo plus CBT for treating cocaine dependence.

A 2-week screening period will be followed by an 8-week treatment phase. Participants will be randomly assigned to receive either 200 mg of modafinil, 400 mg of modafinil, or placebo on a daily basis for the 8 weeks of treatment. During this time, participants will be asked to report the number of days that they use and do not use cocaine. This will be confirmed three times a week with urine tests. Mood, level of daytime sleepiness, and symptoms of cocaine withdrawal and cocaine "high" will be evaluated. Compliance with study medication will be assessed with urine and blood tests. Medication side effects will be monitored through physical examinations, routine lab tests, ECGs, and self-reports. Follow-up evaluations will occur 4 and 8 weeks following the end of treatment.
On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingestenzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (25 weeks).
The present invention relates to a functional cosmetic composition of a Phryma leptostachya var. asiatica Hara extract, and specifically, to a cosmetic composition for skin whitening and reducing skin wrinkles containing the Phryma leptostachya var. asiatica Hara extract as an active ingredient. The Phryma leptostachya var. asiatica Hara extract of the present invention has stability which does not cause side effects to skin, has a mechanism of inhibiting tyrosinase activity thereby inhibiting melanin production so as to have whitening effects, and inhibits hyaluronidase activity thereby preventing the generation of skin wrinkles and aging. Therefore, the composition having the same as an active ingredient of the present invention can be used for a material of functional cosmetics for skin whitening and reducing wrinkles which do not cause irritation to skin.